Press release
Nivolumab Market Size, Market Competitive Landscape, Business Growth, Share, And Forecast To 2033
Nivolumab Market Size
According to The Business Research Company's, The nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.
The nivolumab market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to personalized medicine, emerging indications, global access to cancer care, advancements in combination therapies. Major trends in the forecast period include biomarker-driven treatment, neoantigen vaccines, enhanced immunotherapy regimens, long-term follow-up studies.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report
Market Drivers and Trends:
The rising prevalence of cancer is expected to propel the growth of the nivolumab market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries and either spread to other organs or invade neighboring body parts. Nivolumab is used to manage and treat several types of cancer by keeping cancer cells from suppressing the immune system and allowing the immune system to attack and kill the cancer cells. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase compared to more than 1.8 million new cancer cases diagnosed in 2020. Therefore, the rising prevalence of cancer is driving the growth of the nivolumab market.
Major Companies operating in the nivolumab market are focusing on developing innovative drugs to treat their customers and sustain their position in the market. The development of new drugs can improve treatment outcomes for patients with various diseases. For instance, in May 2022, Bristol-Myers Squibb Co., a US-based pharmaceutical company primarily focusing on cancer, cardiovascular, immunology and fibrotic therapeutic projects, announced that the U.S. Food and Drug Administration (FDA) had approved two nivolumab-based regimens, such as Nivolumab in combination with fluoropyrimidine and platinum-containing chemotherapy and Nivolumab plus Yervoy (ipilimumab), for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13012&type=smp
Major Key Players of the Market:
Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.
Nivolumab Market 2024 Key Insights:
• Nivolumab is expected to grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%.
• Elevated Cancer Prevalence Fuels Expansion Of The Nivolumab Market
• Innovative Drug Development Shapes The Future Of The Nivolumab Market
• North America was the largest region in the nivolumab market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13012&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nivolumab Market Size, Market Competitive Landscape, Business Growth, Share, And Forecast To 2033 here
News-ID: 3666279 • Views: …
More Releases from The Business Research Company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for Nivolumab
Nivolumab Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportuni …
The Nivolumab Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Nivolumab Market?
In the past few years, the market size for nivolumab has seen quick expansion. The market is project to increase from $1.69 billion in 2024 to $1.94…
Nivolumab Market Size, Production, Growth Segments, Business Growth Opportunitie …
The Nivolumab Market Is Set To Grow At An Estimated CAGR Of 6.8% From 2025 To 2034, Rising From $6.5 Billion In 2024 To $12.8 Billion By 2034.
On April 29, 2025, Exactitude Consultancy., Ltd. released a research report titled "Nivolumab Market" This report offers a new perspective on the Nivolumab Market covering an extensive range of aspects including market overview, expenditure analysis, import trends, segmentation, key players, and opportunities spanning.…
Elevated Cancer Prevalence Fuels Expansion Of The Nivolumab Market Driver: Leadi …
How Are the key drivers contributing to the expansion of the nivolumab market?
The nivolumab market is likely to see significant growth due to the increasing instances of cancer. Cancer, a category of diseases that can affect virtually any organ or tissue in the body, is triggered when rogue cells grow uncontrollably, disregarding their established boundaries and invading or spreading to other parts of the body. Nivolumab, a medication used to…
Nivolumab Market expected to reach USD 2,736.83 million by 2030
This Nivolumab market report has been prepared by considering several fragments of the present and upcoming market scenario. The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. It consists of most-detailed market segmentation, thorough analysis of major market players, trends in consumer and supply chain dynamics, and…
Nivolumab Market Share, Industry Analysis And Forecast 2033
The new report published by The Business Research Company, titled Nivolumab Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69…
Nivolumab Global Market Analysis, Trends, Growth, Research And Forecast 2033
The nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.
The nivolumab market size is expected to see rapid growth in the next few years. It…
